Unkind to Mannkind
Last time I mentioned Mannkind and their inhaled-insulin product (Afrezza) around here was when Oliver Brandicourt was announced as taking over at Sanofi. But I’ve had unkind things to say about them over the years, and their retail-investor cult is one of the most bizarre I’ve ever seen. So now that Afrezza is launched, and…